PAREXEL CONSULTING EXPERTS TO PRESENT INSIGHTS INTO ACHIEVING REGULATORY APPROVAL AT THE 2009 BIO INTERNATIONAL CONVENTION
BOSTON, MA, May 14, 2009 — Experts from PAREXEL Consulting will present insights into achieving regulatory approval at the BIO International Convention, to be held May 18 -21, 2009 at the Georgia World Congress Center in Atlanta, Georgia. PAREXEL Consulting is a business unit of PAREXEL International (NASDAQ: PRXL) and leading global consultancy serving the biopharmaceutical and medical device industries. PAREXEL Consulting experts will be on site at the convention to discuss all aspects of biologics development and commercialization, portfolio analysis, and acquisition due diligence with attendees. For more information about these topics visit http://www.parexelconsulting.com/BIO2009.
On Tuesday, May 19 of the convention, PAREXEL Consulting experts will give presentations on the following panels, which are part of the Achieving Regulatory Approval Breakout Session:
Regulatory Best Practices for Emerging Companies and First-Time Filers
Panelist: David Morse, Principal Consultant, PAREXEL Consulting
(8:00 a.m. – 9:30 a.m.)
Is Gaining Drug Approval More Difficult in Europe than the U.S., or Vise Versa?
Panelist: Alberto Grignolo, Ph.D., Corporate Vice President, PAREXEL Consulting
(4:00 p.m. – 5:30 p.m.)
PAREXEL has worked with the top 10 global biotechnology companies, and has helped hundreds of small and mid-size biopharmaceutical companies develop and implement product and regulatory strategies as well as maximize product value at every milestone and phase of development. For information regarding PAREXEL Consulting’s development optimization capabilities, including regulatory services, visit http://www.parexelconsulting.com/services/development-optimization.html.
For more information about the BIO International Convention, which brings together 20,000 life sciences professionals from 60 countries, visit http://convention.bio.org.
# # #
About PAREXEL Consulting
PAREXEL Consulting, a division of PAREXEL International, provides integrated product development services with the goal of helping biopharmaceutical and medical device companies get their products to the market, and keep them on the market. Through a unique fusion of scientific, regulatory, and business expertise PAREXEL Consulting helps clients worldwide manage risk and maximize product and portfolio value at every milestone and during each phase of development.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 69 locations throughout 52 countries around the world, and has over 9,400 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2009 as filed with the SEC on May 8, 2009, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.